Skip to main content
Erschienen in: Medical Oncology 1/2011

01.03.2011 | Original Paper

Clear cell adenocarcinoma of the uterine cervix in a young pregnant woman: a case report with immunohistochemical study

verfasst von: Tadashi Terada

Erschienen in: Medical Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The patient was a 30-year-old-pregnant woman (para 1, gradiva 1) without in utero exposure to diethylstilbestrol. A papillary and flat lesion was found by colposcopy in the uterine cervix in the routine examination at 10 pregnancy weeks. Biopsies showed papillary and tubular proliferation of malignant cells with clear glycogen-rich cytoplasm and malignant hobnail cells and were diagnosed as clear cell adenocarcinoma. The patient was treated by radical hysterectomy. The lesion of the cervix (10 × 15 × 5 mm) was clear cell adenocarcinoma with mild invasion into shallow myometrium (pTIb). An immunohistochemical study showed that the tumor cells were positive for pancytokeratins (AE1/3, CAM5.2, KL-1, and polyclonal wide), cytokeratin (CK) 7, CK8, CK18, CK19, epithelial membrane antigen, CA 125, p53 protein, and Ki-67 antigen (labeling = 95%). The tumor cells were negative for high-molecular weight CK (34βE12), CK5/6, CK14, CK20, vimentin, AFP, CEA, desmin, S100 protein, α-smooth muscle antigen, CD34, estrogen receptor, progesterone receptor, chromogranin, synaptophysin, neuron-specific enolase, and CD56. The patient is now of free of tumor. In the English literature, the present case is the second case of cervical clear cell adenocarcinoma during pregnancy, and the first case of cervical clear cell carcinoma investigating a wide range of immunoreactive antigens.
Literatur
1.
Zurück zum Zitat Yabushita H, Kanyama K, Sekiya R, Noguchi M, Wakatsuki A. Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent. Int J Clin Oncol. 2008;13:552–4.PubMedCrossRef Yabushita H, Kanyama K, Sekiya R, Noguchi M, Wakatsuki A. Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent. Int J Clin Oncol. 2008;13:552–4.PubMedCrossRef
2.
Zurück zum Zitat Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, et al. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. 2008;109:335–9.PubMedCrossRef Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, et al. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. 2008;109:335–9.PubMedCrossRef
3.
Zurück zum Zitat Seki H, Takada T, Sodemoto T, Hoshino H, Saitoh K, Uekusa T. A young woman with clear cell adenocarcinoma of the uterine cervix. Int J Clin Oncol. 2003;8:399–404.PubMedCrossRef Seki H, Takada T, Sodemoto T, Hoshino H, Saitoh K, Uekusa T. A young woman with clear cell adenocarcinoma of the uterine cervix. Int J Clin Oncol. 2003;8:399–404.PubMedCrossRef
4.
Zurück zum Zitat Inoue S, Matsuo I, Shimokawa K, Tohya T, Maeyama M. A case of clear cell adenocarcinoma of the uterine cervix in pregnancy. Gynecol Oncol. 1986;24:120–5.PubMedCrossRef Inoue S, Matsuo I, Shimokawa K, Tohya T, Maeyama M. A case of clear cell adenocarcinoma of the uterine cervix in pregnancy. Gynecol Oncol. 1986;24:120–5.PubMedCrossRef
5.
Zurück zum Zitat Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 52:740–746. Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 52:740–746.
6.
Zurück zum Zitat Tavassoli FA, Devilee P, editors. WHO Classification of tumous. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC press; 2003. Tavassoli FA, Devilee P, editors. WHO Classification of tumous. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC press; 2003.
7.
Zurück zum Zitat Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecological tract. Int J Gynecol Pathol. 2001;20:252–9.PubMedCrossRef Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecological tract. Int J Gynecol Pathol. 2001;20:252–9.PubMedCrossRef
8.
Zurück zum Zitat Murta EF, Nomemelli RS, Ferreira FA, Lima MA. Ovarian clear cell adenocarcinoma with endometriosis: a case report with immunohistochemical study. Eur J Gynecol Oncol. 2007;28:403–5. Murta EF, Nomemelli RS, Ferreira FA, Lima MA. Ovarian clear cell adenocarcinoma with endometriosis: a case report with immunohistochemical study. Eur J Gynecol Oncol. 2007;28:403–5.
9.
Zurück zum Zitat Nolan LP, Heartley MK. The value of immunohistochemistry in distinguishing between clear cell carcinoma of kidney and ovary. Int J Gynecol Pathol. 2001;20:155–9.PubMedCrossRef Nolan LP, Heartley MK. The value of immunohistochemistry in distinguishing between clear cell carcinoma of kidney and ovary. Int J Gynecol Pathol. 2001;20:155–9.PubMedCrossRef
10.
Zurück zum Zitat Howell NR, Zheng W, Cheng L, Tornos C, Kane P, Pearl M, et al. Carcinoma of the ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int J Gynecol Pathol. 2007;26:134–40.PubMedCrossRef Howell NR, Zheng W, Cheng L, Tornos C, Kane P, Pearl M, et al. Carcinoma of the ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int J Gynecol Pathol. 2007;26:134–40.PubMedCrossRef
Metadaten
Titel
Clear cell adenocarcinoma of the uterine cervix in a young pregnant woman: a case report with immunohistochemical study
verfasst von
Tadashi Terada
Publikationsdatum
01.03.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9410-x

Weitere Artikel der Ausgabe 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.